anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The formed component (3) for dental prosthesis is coated (2) on all sides, with at least one or more layers of organic, inorganic or metal materials and/or a suitable combination of these materials. Pref. materials are filled and/or unfilled and/or fibre-reinforced plastics, organic or inorganic composites, ceramics, carbon materials such as graphite or CFC materials and/or metals and/or metal alloys or the initial stages of these materials. The formed component (3) can either be built up on a positive model (1) by deposition, pressing into place or coasting, and the hardened and/or converted by chemical-physical action. Or it can be a substractive operation from raw material or a semi-finished workpiece. The chemical-physical action to convert the initial materials can be a cross linking reaction and/or sintering carbonising process, carried out after surface coating of the formed component or after the prosthesis is finished, so that each component can be prefabricated with or without a coating. The formed part (3) remains in the cpd. structure, also after coating (2), with the required three-dimensional geometry. USE-ADVANTAGE - The dental prosthesis can be coated directly and on all sides such as a dental plate, with precision in a single operation with a choice of materials to give the required strength in a thin structure. Where gold is used, only a thin layer is required which reduces gold usage, with reduced weight and material costs.
Dectin-1 is a well-characterized C-type lectin receptor involved in anti-fungal immunity through the recognition of polysaccharides; however, molecular mechanisms and outcomes initiated through self-recognition have not been fully understood. Here, we purified a water-soluble fraction from mouse liver that acts as a Dectin-1 agonist. To address the physiological relevance of this recognition, we utilized sterile liver inflammation models. The CCl4-induced hepatitis model showed that Dectin-1 deficiency led to reduced inflammation through decreased inflammatory cell infiltration and lower pro-inflammatory cytokine levels. Moreover, in a NASH model induced by streptozotocin and a high-fat diet, hepatic inflammation and fibrosis were ameliorated in Dectin-1-deficient mice. The Dectin-1 agonist activity was increased in the water-soluble fraction from NASH mice, suggesting a potential pathogenic cycle between Dectin-1 activation and hepatitis progression. In vivo administration of the fraction into mice induced hepatic inflammation. These results highlight a role of self-recognition through Dectin-1 that triggers hepatic innate immune responses and contributes to the exacerbation of inflammation in pathogenic settings. Thus, the blockade of this axis may provide a therapeutic option for liver inflammatory diseases.
Hyperuricemia is a common metabolic disorder. It can result from a decreased renal uric acid excretion, increased urate production, or both. The classical association with clinical gout is well-known. The principal indications for uric acid-lowering therapy, including allopurinol, probenecid and sulfinpyrazone, are the patients with gout history, macroscopic subcutaneous tophi, frequent attacks of gouty arthritis, or a documented state of uric acid overproduction. Hyperuricemia is often associated with metabolic syndrome,which is known a percursor of atherosclerosis. For the gout attack only 5% per year of the hyperuricemic population, medical management is not indicated for patients without gouty arthritis. Diet control is the leading way to control serum uric acid level, but usually it is not enough. So how to management hyperuricemia is important and is a potential management.Histidine-containing dipeptides such as Anserine and Carnosine have been studied extensively in recent years. These dipeptides were shown to be effective in acting as buffering agents against protons developed during anaerobic exercise. Anserine and Carnosine also have strong anti-oxidant activity, anti-cancer activity, immuno-response modulation, fat reduction and enhanced wound healing functions. The Yaizu Suisankagaku Industry Company have developed industrial production process to extract and purify the dipeptides from Bonito and Tuna. The extract, named Marine Active, was able to offer anti-fatigue activity by animal trial data. Human clinical trials showed reduction of creatine phosphokinase activity and sero-uric acid. Randomize, double blind clinical trial is entrust to our hospital. This study design is blood sampling from the health men who take 1 gm of marine active to analyse the pharmacokinetics of anserine.
The invention provides a composition of a membrane for blocking drug release and a preparation method thereof. Compared with the prior art, the invention has the following technical effects: 1. the components do not need to be added with a surfactant for neutralizing charges. 2. The blocking drug release capacity is stronger. 3. The process problem caused by static electricity in the process can be reduced.
Amiodarone can cause fetal harm when administered to a pregnant woman. Although amiodarone use during pregnancy is uncommon, there have been a small number of published reports of congenital goiter/hypothyroidism and hyperthyroidism. If amiodarone hydrochloride tablets are used during pregnancy, or if the patient becomes pregnant while taking amiodarone, the patient should be apprised of the potential hazard to the fetus.

In general, amiodarone hydrochloride tablets should be used during pregnancy only if the potential benefit to the mother justifies the unknown risk to the fetus.

In pregnant rats and rabbits, amiodarone hydrochloride in doses of 25 mg/kg/day (approximately 0.4 and 0.9 times, respectively, the maximum recommended human maintenance dose*) had no adverse effects on the fetus. In the rabbit, 75 mg/kg/day (approximately 2.7 times the maximum recommended human maintenance dose*) caused abortions in greater than 90% of the animals. In the rat, doses of 50 mg/kg/day or more were associated with slight displacement of the testes and an increased incidence of incomplete ossification of some skull and digital bones; at 100 mg/kg/day or more, fetal body weights were reduced; at 200 mg/kg/day, there was an increased incidence of fetal resorption. (These doses in the rat are approximately 0.8, 1.6 and 3.2 times the maximum recommended human maintenance dose*). Adverse effects on fetal growth and survival also were noted in one of two strains of mice at a dose of 5 mg/kg/day (approximately 0.04 times the maximum recommended human maintenance dose*).

* 600 mg in a 50 kg patient (doses compared on a body surface area basis)
LR: Lactated Ringer solution. Patients in the LR treatment arm will receive fluid therapy based on lactated Ringer's solution for a minimum of 48 hours.
The invention belongs to the biological pharmacy field, and relates to a long-acting interferon, a preparation method therefor and applications thereof. The long-acting interferon comprises a polysialic-acid-modified interferon and a long-acting interferon recombination fusion protein. The polysialic acid is subjected to activation by utilization of sodium periodate. The activated polysialic acid reacts with an interferon to form a conjugate in the presence of sodium cyanoborohydride. The recombination fusion protein is composed of an N-end interferon and C-end naturally-existed hydrophilic polypeptides without repeated sequences. The fusion protein can be expressed in escherichia coli with high efficiency, and the preparation technology is simple and can be used for production preparation for large-scale medicine-level fusion proteins. The long-acting interferon can be used for treatment of virus infectious diseases of hepatitis virus, SARS, herpes simplex virus and the like, and is used for treatment of malignant tumors of malignant neuroglioma, lung cancer and the like and other cell proliferative diseases.
The invention comprises magnesium carbonato hydroxoaluminates of formula: Mgn [Al2(OH)5+2n,.HCO3] where n is from 1 to 5.  The compounds are prepared by the following methods: reacting a solution of magnesium bicarbonate or a solution of a magnesium salt and sodium bicarbonate with a solution of an alkali aluminate, e.g. sodium aluminate; reacting a solution of salts (e.g. chlorides) of aluminium and magnesium with sodium hydroxide and sodium carbonate; suspending a magnesium hydroxoaluminate in a solution containing bicarbonate ions (e.g. a solution of magnesium bicarbonate); reacting a solution of aluminium and magnesium salts with sodium hydroxide, and adding sodium bicarbonate followed by a mixture of sodium hydroxide and sodium bicarbonate to precipitate all the magnesium; reacting a solution of aluminium and magnesium salts with a solution of sodium carbonate preferably in the presence of ammonium chloride; and reacting a slurry of basic magnesium carbonate and sodium carbonate with a solution of aluminium chloride.  Examples are given.
Tyrosine kinase inhibitors (TKIs) have transformed cancer treatment but are associated with cardiovascular toxicity, including heart failure. This review examines the cardiotoxicity of pazopanib, a VEGFR-TKI, through two case reports and explores potential mechanisms. The importance of vigilant clinical monitoring to prevent cardiac dysfunction in cancer patients receiving pazopanib is emphasized. We present two cases of acute heart failure following pazopanib treatment. Case 1 involves a comorbidity-free, 62-year-old woman with metastatic renal cell carcinoma who experienced irreversible heart failure. In case 2, a 40-year-old woman with a history of anthracycline-containing chemotherapy developed reversible left ventricular systolic dysfunction following pazopanib discontinuation. Both patients received appropriate management for their heart failure symptoms. Case 1's condition rapidly deteriorated, leading to her unfortunate demise 3 months after starting pazopanib. In contrast, case 2's cardiac function improved after discontinuing pazopanib. The advent of TKIs has revolutionized cancer treatment, but their association with cardiovascular toxicity necessitates meticulous monitoring of patients. The cases presented here highlight the importance of recognizing and managing cardiotoxicity, particularly in patients without prior cardiovascular risk factors. Understanding the underlying mechanisms and risk factors for TKI-induced heart failure is crucial to optimize patient care and treatment outcomes. Oncologists should be vigilant in identifying clinical symptoms and closely monitoring cardiac function throughout TKI therapy.
The present invention relates to artificial tears. The artificial tears are characterized in that the artificial tears contain water, water solubility chitin derivatives, pH modifying agents, osmotic pressure modifying agents and sterilizing agents. The proportion ranges of the ingredients by weight are respectively 1000:1 to 6:4 to 8:5 to 8:0.001 to 0.3. The artificial tears have the advantages that the biological material water solubility chitin derivatives are used as principal raw materials, the preparing method is simple, the artificial tears absorb moisture, the moisture keeping performance is good, the artificial tears do not contain general chemistry preservatives, and the artificial tears perform the functions of bacteriostasis and sterilization against a plurality of bacteria. When the concentration is low, the artificial tears have higher viscosity as well as a shear thinning characteristic. The artificial tears conform to the requirements of tears. The artificial tears not only do not damage eyes, but also perform a better protective function for retina.
Four CE children with CAS will be recruited and receive two versions of the DTTC treatment (i.e., DTTC in English \[DTTC-E\] and DTTC in Cantonese \[DTTC-C\]). After the initial assessment and baseline probe sessions, all the participants will be randomly assigned to receive either DTTC-E or DTTC-C in the first 6-week treatment phase. Then, the between-treatment probe sessions will be conducted during a 2-week washout period. This will be followed by the second 6-week treatment phase, which will be the other version of DTTC. Post-treatment probe sessions will be conducted one week and one month after completion of the second treatment.

Participants' speech productions will be transcribed and evaluated based on their accuracy in phonemes, stress, and tone. Growth curve analysis (Mirman, 2014) will be conducted to examine the group differences in the outcome measures across the treatment sessions.
All subjects will undergo fast MR in addition to Computerized Tomography (CT) (the current criterion standard). Fast MR will be interpreted independently for research purposes by 2 blinded radiologists. Consensus interpretation will be compared to the clinical reading of the CT.
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the second leading cause of cancer-related deaths in the world. Because HCC is insidious and early diagnosis is difficult, most patients have locally advanced or distant metastasis at the time of diagnosis. So they are not suitable candidates for curative treatments by resection or transplantation. Currently, Sorafenib is the only choice approved by FDA for advanced HCC, although it prolongs the survival for less than 3 months. Transarterial chemoembolization (TACE) is an important method of minimally invasive therapy in the comprehensive treatment of liver cancer. As a kind of combined treatment, it can obviously prolong the survival time of the patients. Recently, metabolomics studies of HCC have shown that typical Warburg effect was observed in hepatoma carcinoma cells. Arginine hydrochloride is a new anticancer drug in the treatment of liver cancer, which is mainly aimed at the pathway of energy metabolism. Trimetazidine hydrochloride may play an anti-tumor role by inhibiting fatty acid oxidation. The investigators have been proceeding this trial to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with arginine hydrochloride and trimetazidine hydrochloride tablets in the treatment of patients with hepatocellular carcinoma.
From November 2004 to June 2020, there were more than 200 patients with acute TAAD patients who underwent aortic surgery at our hospital. The research protocol used in this study was approved by the institutional review board of MacKay Memorial Hospital (IRB number: 21MMHIS005e). Of all the patients in the study period, there were 34 patients (defined as study group) who sought for medical attention with symptoms for several days (median 5 days, range 3-7 days) or deferred aortic surgery several days later (median 3 days, range 2-7 days) even though acute TAAD was diagnosed on the same day when chest pain or back pain occurred. The mean age at presentation was 60.2 +/- 13.2 years (range 33.4\~83.5 years). All the patients in the study group were divided into 3 groups: DP group (n=22) with acute TAAD diagnosis delayed by patient but received prompt aortic surgery; DD group (n=4) with acute TAAD diagnosis delayed by patient and received deferred aortic surgery; ID group (n=8) with acute TAAD diagnosis on the same day when the symptoms occurred but received deferred aortic surgery several days later. For reducing the selection bias, propensity score matching (PSM) was used to match the study group with the control group from all the patients treated at our hospital during the study period. Comparison between the two groups was performed.
Adolescents with a concussion (n=120) will undergo neuroimaging (MEG and MRI) and neuropsychology assessments at two time points in the acute and chronic periods after injury, respectively. Brain imaging injury measures will be compared to a control normative database we will create. These brain measures will also be associated with cognitive and clinical outcomes.
Bile acid sequestering agents, such as cholestyramine and colestipol, may interfere with the action of Chenodiol by reducing its absorption. Aluminum-based antacids have been shown to absorb bile acids in vitro and may be expected to interfere with Chenodiol in the same manner as the sequestering agents. Estrogen, oral contraceptive and collaborate (and perhaps other lipid-lowering drugs) increase biliary cholesterol secretion, and the incidence of cholesterol gallstones, hence, may counteract the effectiveness of Chenodiol.

Due to its hepatotoxicity, Chenodiol can affect the pharmacodynamics of coumarin and its derivatives, causing unexpected prolongation of the prothrombin time and hemorrhages. Patients on concomitant therapy with Chenodiol and coumarin or its derivatives should be monitored carefully. If prolongation of prothrombin time is observed, the coumarin dosage should be readjusted to give a prothrombin time 1½ to 2 times normal. If necessary Chenodiol should be discontinued.
Human papillomavirus (HPV) genotyping is widely used, particularly in combination with high-risk (HR) HPV tests for cervical cancer screening. We developed a genotyping method using sequences of approximately 800 bp in the E6/E7 region obtained by PacBio single molecule real-time sequencing (SMRT) and evaluated its performance against MY09-11 L1 sequencing and after the APTIMA HPV genotyping assay. The levels of concordance of PacBio E6/E7 SMRT sequencing with MY09-11 L1 sequencing and APTIMA HPV genotyping were 100% and 90.8%, respectively. The sensitivity of PacBio E6/EA7 SMRT was slightly greater than that of L1 sequencing and, as expected, lower than that of HR-HPV tests. In the context of cervical cancer screening, PacBio E6/E7 SMRT is then best used after a positive HPV test. PacBio E6/E7 SMRT genotyping is an attractive alternative for HR and LR-HPV genotyping of clinical samples. PacBio SMRT sequencing provides unbiased genotyping and can detect multiple HPV infections and haplotypes within a genotype.
The ABC-teen is a universal parenting program where two trained leaders meet parents meet in groups (10-15 parents) at four occasions (2.5 hours each). One or two follow-up meetings are also offered. The themes that are covered during the meetings include: spending time together, communication, parental stress management and emotion regulation, and problem solving/conflict resolution.
A method and system for providing more relevant search results and recommendation from a food database is disclosed. The method includes receiving a query, a first candidate food, and a second candidate food. The method includes generating vectors based on the query and food names of the first and second candidate foods using at least one embedding function of a machine learning model. The method includes determining nutrition content vectors from the nutritional data of the first and second candidate foods. The method includes generating a nutrition content vector based on the query using another embedding function of the machine learning model. The method includes determining which of the first and second candidate food is more relevant to the query based at least in part on the nutrition content vectors. The method includes providing search results or recommendation based on the determined relevance.
Patents are treated with interferon alfa 2a 180μg hypodermic injection once per week for 48 weeks. Then, interferon alfa 2a will be stopped if there is HBsAg clearance. Else, oral tenofovir 300mg once per day will be used if HBsAg is positive.
1. The potential growth of the chemical and physical components of males and females of the Cobb 700 strain was measured from hatch to 15 weeks of age.2. A four-phase ad libitum feeding programme was used to feed 200 chicks of each sex. All birds were weighed weekly. Ten birds per sex were sampled at 0, 7, 14, 28, 42, 56, 70, 84 and 105 d of age. They were weighed before and after plucking to determine the weight of feathers. Physical parts were measured on defeathered birds, whereafter these components were combined, minced, freeze dried to measure water content, and then analysed for protein, lipid and ash content.3. Mature body weights of males and females averaged 8.38 and 6.94 kg, respectively, mature body protein weights averaged 1.48 and 1.19 kg and mature body lipid contents averaged 1.08 and 1.54 kg, respectively.4. Rates of maturing of the empty feather-free body weights of males and females averaged 0.0417 and 0.0402/d, respectively. All chemical and physical components within a sex, other than feathers, had the same rate of maturing. The rate of maturing of feathers, calculated by iteration, in males was lower than in females (0.0324 vs. 0.0357/d) and the mature weight was higher (435 vs. 372 g).5. The ratios of the chemical components to feather-free body protein at maturity for males and females were, for water, 3.80 and 3.34; for lipid, 0.73 and 1.29; and for ash, 0.13 and 0.19, respectively. Separate equations were required for males and females to describe the allometric relationship between lipid and protein in the feather-free body.6. Mature body weights of broilers in this trial were considerably higher than those measured using the same protocol 28 years ago, whereas rates of maturing have remained the same.
BACKGROUND & AIMS: Weight loss in individuals with obesity and overweight leads to metabolic and health benefits but also poses the risk of muscle mass reduction. This systematic review and meta-analysis of randomized controlled trials aims to determine the initial protein amount necessary for achieving weight loss while maintaining muscle mass, strength, and physical function in adults with overweight and obesity.
METHODS: Relevant literature databases, including Medical Literature Analysis and Retrieval System Online (Medline), Excerpta Medica (Embase), the Cumulative Index to Nursing and Allied Health Literature (CINHAL), and Web of Science, were electronically searched up to 15 March 2023. We examined the effect of additional protein intake on muscle mass, strength, and physical function in adults with overweight or obesity targeting weight loss. The risk of bias was assessed using the Cochrane RoB 2.0 tool. Results were synthesized using standardized mean differences (SMD) and 95% confidence intervals (CI) via a random-effects model.
RESULTS: Forty-seven studies (n = 3218) were included. In the muscle mass analysis, twenty-eight trials with 1989 participants were encompassed. Results indicated that increased protein intake significantly prevents muscle mass decline in adults with overweight or obesity aiming for weight loss (SMD 0.75; 95% CI 0.41 to 1.10; p < 0.001). Enhanced protein intake did not significantly prevent decreases in muscle strength and physical function. An intake exceeding 1.3 g/kg/day is anticipated to increase muscle mass, while an intake below 1.0 g/kg/day is associated with a higher risk of muscle mass decline. The risk of bias in studies regarding muscle mass ranged from low to high.
CONCLUSIONS: Adults with overweight or obesity and aim for weight loss can more effectively retain muscle mass through higher protein intake, as opposed to no protein intake enhancement.